The most commonly reported Retatrutide side effects in Phase 2 studies were gastrointestinal: [1][2] These effects were generally managed through gradual dose escalation and were consistent with the class profile observed across GLP-1-based therapies
The theoretical concern with semaglutide and oral drugs is about absorption timing, not metabolism, and that concern was tested directly against omeprazole and did not materialize
Half-life: ~4 hours (short-acting typically studied twice daily)
Concluding Remarks The present study points to GLP-1 signaling as a potential target for treating food-related behavioral problems in intellectual disability syndromes with ASD
From : Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) P referred R eporting I tems for S ystematic Reviews and Meta- A nalyses: The PRISMA Statement
Just relax and let the strip do its work